

60 - References

References

Depression and anxiety disorders CHAPTER 3 References

1. Satel SL, et al. Stimulants in the treatment of depression: a critical overview. *J Clin Psychiatry* 1989; 50:241-249.
2. Warneke L. Psychostimulants in psychiatry. *Can J Psychiatry* 1990; 35:3-10.
3. Goss AJ, et al. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. *J Clin Psychiatry* 2013; 74:1101-1107.
4. Candy M, et al. Psychostimulants for depression. *Cochrane Database Syst Rev* 2008; (2):CD006722.
5. McIntyre RS, et al. The efficacy of psychostimulants in major depressive episodes: a systematic review and meta-analysis. *J Clin Psychopharmacol* 2017; 37:412-418.
6. Bahji A, et al. Comparative efficacy and safety of stimulant-type medications for depression: a systematic review and network meta-analysis. *J Affect Disord* 2021; 292:416-423.
7. Lundt L. Modafinil treatment in patients with seasonal affective disorder/winter depression: an open-label pilot study. *J Affect Disord* 2004; 81:173-178.
8. Kaufman KR, et al. Modafinil monotherapy in depression. *Eur Psychiatry* 2002; 17:167-169.
9. Hegerl U, et al. Why do stimulants not work in typical depression? *Aust N Z J Psychiatry* 2017; 51:20-22.
10. Little KY. d-Amphetamine versus methylphenidate effects in depressed inpatients. *J Clin Psychiatry* 1993; 54:349-355.
11. Robin AA, et al. A controlled trial of methylphenidate (ritalin) in the treatment of depressive states. *J Neurol Neurosurg Psychiatry* 1958; 21:55-57.
12. Lavretsky H, et al. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. *J Clin Psychiatry* 2003; 64:1410-1414.
13. Postolache TT, et al. Early augmentation of sertraline with methylphenidate. *J Clin Psychiatry* 1999; 60:123-124.
14. Gwirtsman HE, et al. The antidepressant response to tricyclics in major depressives is accelerated with adjunctive use of methylphenidate. *Psychopharmacol Bull* 1994; 30:157-164.
15. Giacobbe P, et al. Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: a meta-analysis of randomized controlled trials. *J Affect Disord* 2018; 226:294-300.

16. Fava M, et al. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. *Ann Clin Psychiatry* 2007; 19:153-159.
17. Kerr CW, et al. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. *J Pain Symptom Manage* 2012; 43:68-77.
18. Rasmussen NA, et al. Modafinil augmentation in depressed patients with partial response to antidepressants: a pilot study on self-reported symptoms covered by the major depression inventory (MDI) and the symptom checklist (SCL-92). *Nord J Psychiatry* 2005; 59:173-178.
19. DeBattista C, et al. A prospective trial of modafinil as an adjunctive treatment of major depression. *J Clin Psychopharmacol* 2004; 24:87-90.
20. Markovitz PJ, et al. An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy. *J Clin Psychopharmacol* 2003; 23:207-209.
21. Ravindran AV, et al. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. *J Clin Psychiatry* 2008; 69:87-94.
22. Ghanean H, et al. Fatigue in patients with major depressive disorder: prevalence, burden and pharmacological approaches to management. *CNS Drugs* 2018; 32:65-74.
23. Vaccarino SR, et al. The potential procognitive effects of modafinil in major depressive disorder: a systematic review. *J Clin Psychiatry* 2019; 80:19r12767.
24. Fawcett J, et al. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment refractory depression. *J Clin Psychopharmacol* 1991; 11:127-132.
25. Israel JA. Combining stimulants and monoamine oxidase inhibitors: a reexamination of the literature and a report of a new treatment combination. *Prim Care Companion CNS Disord* 2015; 17:10.4088/PCC.4015br01836.
26. Rohde C, et al. The use of stimulants in depression: results from a self-controlled register study. *Aust N Z J Psychiatry* 2020; 54:808-817.
27. Parker G, et al. Do the old psychostimulant drugs have a role in managing treatment-resistant depression? *Acta Psychiatr Scand* 2010; 121:308-314.
28. Richards C, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy. *J Psychopharmacol* 2017; 31:1190-1203.
29. Szmulewicz AG, et al. Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis. *Acta Psychiatr Scand* 2017; 135:527-538.
30. Perugi G, et al. Use of stimulants in bipolar disorder. *Curr Psychiatry Rep* 2017; 19:7.
31. Frye MA, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. *Am J Psychiatry* 2007; 164:1242-1249.
32. Tsapakis EM, et al. Adjunctive treatment with psychostimulants and stimulant-like drugs for resistant bipolar depression: a systematic review and meta-analysis. *CNS Spectr* 2020; doi: 10.1017/S109285292000156X.
33. Nunez NA, et al. Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: a meta-analysis of randomized controlled trials. *Bipolar Disord* 2020; 22:109-120.
34. Chiorean A, et al. Prescribed psychostimulants and other pro-cognitive medications in bipolar disorder: a systematic review and meta-analysis of recurrence of manic symptoms. *Bipolar Disord* 2024; 26:418-430.

35. Kwok WY, et al. High-dose armodafinil in treatment-refractory bipolar depression. *Ann Clin Psychiatry* 2023; 35:195–198.

392 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3

36. Dell’Osso B, et al. Assessing the roles of stimulants/stimulant-like drugs and dopamine-agonists in the treatment of bipolar depression. *Curr Psychiatry Rep* 2013; 15:378.

37. McElroy SL, et al. Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo-controlled trial. *Int Clin Psychopharmacol* 2015; 30:6–13.

38. Fernandez F, et al. Methylphenidate for depressive disorders in cancer patients. *Psychosomatics* 1987; 28:455–461.

39. Macleod AD. Methylphenidate in terminal depression. *J Pain Symptom Manage* 1998; 16:193–198.

40. Homsy J, et al. Methylphenidate for depression in hospice practice. *Am J Hospice Palliat Care* 2000; 17:393–398.

41. Sarhill N, et al. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. *Am J Hosp Palliat Care* 2001; 18:187–192.

42. Homsy J, et al. A phase II study of methylphenidate for depression in advanced cancer. *Am J Hosp Palliat Care* 2001; 18:403–407.

43. Burns MM, et al. Dextroamphetamine treatment for depression in terminally ill patients. *Psychosomatics* 1994; 35:80–83.

44. Olin J, et al. Psychostimulants for depression in hospitalized cancer patients. *Psychosomatics* 1996; 37:57–62.

45. Ng CG, et al. Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-week, randomized, double-blinded, placebo-controlled study. *Eur Neuropsychopharmacol* 2014; 24:491–498.

46. Sullivan DR, et al. Randomized, double-blind, placebo-controlled study of methylphenidate for the treatment of depression in SSRI-treated cancer patients receiving palliative care. *Psychooncology* 2017; 26:1763–1769.

47. Conley CC, et al. Modafinil moderates the relationship between cancer-related fatigue and depression in 541 patients receiving chemotherapy. *J Clin Psychopharmacol* 2016; 36:82–85.

48. Padala PR, et al. Methylphenidate for apathy in community-dwelling older veterans with mild Alzheimer’s disease: a double-blind, randomized, placebo-controlled trial. *Am J Psychiatry* 2018; 175:159–168.

49. Kaplitz SE. Withdrawn, apathetic geriatric patients responsive to methylphenidate. *J Am Geriatr Soc* 1975; 23:271–276.

50. Jacobson A. The use of ritalin in psychotherapy of depressions of the aged. *Psychiatr Q* 1958; 32:474–483.

51. Wallace AE, et al. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. *Am J Psychiatry* 1995; 152:929–931.

52. Smith KR, et al. Methylphenidate use in geriatric depression: a systematic review. *Int J Geriatr Psychiatry* 2021; 36:1304–1312.

53. Grade C, et al. Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. *Arch Phys Med Rehabil* 1998; 79:1047–1050.

54. Lazarus LW, et al. Efficacy and side effects of methylphenidate for poststroke depression. *J Clin Psychiatry* 1992; 53:447–449.

55. Lingam VR, et al. Methylphenidate in treating poststroke depression. *J Clin Psychiatry* 1988; 49:151–153.

56. Delbari A, et al. Effect of methylphenidate and/or levodopa combined with physiotherapy on mood and cognition after stroke: a randomized, double-blind, placebo-controlled trial. *Eur Neurol* 2011; 66:7–13.

57. Sugden SG, et al. Modafinil monotherapy in poststroke depression. *Psychosomatics* 2004; 45:80–81.

58. Rosenberg PB, et al. Methylphenidate in depressed medically ill patients. *J Clin Psychiatry* 1991; 52:263–267.

59. Woods SW, et al. Psychostimulant treatment of depressive disorders secondary to medical illness. *J Clin Psychiatry* 1986; 47:12–15.

60. Kaufmann MW, et al. The use of d-amphetamine in medically ill depressed patients. *J Clin Psychiatry* 1982; 43:463–464.

61. Wagner GJ, et al. Dexamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study. *J Psychosom Res* 1997; 42:407–411.

62. Wagner GJ, et al. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. *J Clin Psychiatry* 2000; 61:436–440.

63. Cheng YS, et al. Therapeutic benefits of pharmacologic

and nonpharmacologic treatments for depressive symptoms after traumatic brain injury: a systematic review and network meta-analysis. *J Psychiatry Neurosci* 2021; 46:e196–e207.

Revision #1

Created 2026-01-04 20:15:35 UTC by Omar Ayman

Updated 2026-01-04 20:15:35 UTC by Omar Ayman